Celyad's NKR phase I trial shows encouraging results
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
Pharmaceuticals, Biotechnology and Life Sciences
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
Surgical Innovations Group has completed the acquisition of the laparoscopic instruments …
Professor Gerard Evan, FRS, has joined Scientific Advisory Board of Avacta Group, the developer of Affimer biotherapeutics and research reagents.
Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck…
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.
FDA granted accelerated approval to Lartruvo (olaratumab) injection, in combination with doxorubicin, for the treatment of adult patients…
Cardinal Health has announced on Thursday that the board of directors approved a regular quarterly dividend…
Gelesis, focused on developing first-in-class products to safely induce weight loss and improve glycaemic control, has presented new data for its second product candidate, Gelesis200
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
Alkermes, a global biopharmaceutical company developing medicines for the treatment of central nervous system…